X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Skytrofa (lonapegsomatropin) is designed to deliver unmodified somatropin, which is used for treatment of children and adolescents with growth failure due to insufficient endogenous growth hormone secretion. Its BLA has been accepted in China.
Lead Product(s): Lonapegsomatropin
Therapeutic Area: Endocrinology Product Name: Skytrofa
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
TransCon CNP (c-type natriuretic peptide prodrug) is a FGFR 3 inhibitor. It is being evaluated for the treatment of children with achondroplasia (ACH) aged 2 to 10 years.
Lead Product(s): C-type Natriuretic Peptide Prodrug
Therapeutic Area: Genetic Disease Product Name: TransCon CNP
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Details:
TransCon PTH (palopegteriparatide) is designed to restore physiologic levels and activity of parathyroid hormone (PTH) throughout 24 hours per day, thereby addressing full aspects of the HP disease, including normalizing serum and urinary calcium and serum phosphate levels.
Lead Product(s): Palopegteriparatide
Therapeutic Area: Endocrinology Product Name: TransCon PTH
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
ACP-011 (lonapegsomatropin), a long-acting prodrug of unmodified somatropin is being investigated as a once-weekly injection in children with growth hormone deficiency (GHD) in China.
Lead Product(s): Lonapegsomatropin
Therapeutic Area: Endocrinology Product Name: ACP-011
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Ascendis Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
Top-line results of TransCon hGH, from the trial indicate that lonapegsomatropin was well-tolerated and with comparable safety to daily growth hormone. The safety profile of lonapegsomatropin in Chinese children with GHD was consistent.
Lead Product(s): Lonapegsomatropin
Therapeutic Area: Endocrinology Product Name: TransCon hGH
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
The primary endpoints of the study include evaluating the safety, tolerability and efficacy of once-daily subcutaneous injection of TransCon™ PTH in adults with HP.
Lead Product(s): TransCon PTH
Therapeutic Area: Endocrinology Product Name: TransCon PTH
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
The multicenter, randomized, open-label and parallel control study aims to demonstrate noninferiority in annualized height velocity following weekly injections of TransCon hGH compared to once daily dosing of hGH after 52 weeks of treatment in prepubertal children with GHD.
Lead Product(s): TransCon PTH
Therapeutic Area: Endocrinology Product Name: TransCon PTH
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Ascendis Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
Details:
Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commercialization.
Lead Product(s): Lonapegsomatropin
Therapeutic Area: Endocrinology Product Name: TransCon hGH
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Sequoia China
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 09, 2021
Details:
China Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has approved VISEN's IND application to conduct a phase 2 clinical trial of TransCon TM C-Type Natriuretic Peptide (CNP) for patients with achondroplasia (ACH).
Lead Product(s): Natriuretic Peptide, C-Type
Therapeutic Area: Genetic Disease Product Name: TransCon CNP
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
